Mometasone furoate in preventing radiation dermatitis in patients undergoing radiation therapy to the breast or chest wall for invasive breast cancer or ductal carcinoma in situ

Journal of Drugs in Dermatology,  May, 2007  

• E-mail
• Print
• Link

Sponsors and Collaborators: North Central Cancer Treatment Group and National Cancer Institute (NCI). This randomized phase III trial is studying mometasone furoate to see how well it works compared to a placebo in preventing radiation dermatitis in patients undergoing radiation therapy to the breast or chest wall for invasive breast cancer or ductal carcinoma in situ.

Condition           Intervention                           Phase

Breast Cancer       Drug: mometasone furoate               Phase III
Dermatologic        Procedure: complications of therapy
  Complications       assessment/management
Radiation Toxicity  Procedure: dermatologic
Skin Reactions        complications management
  Secondary to      Procedure: endocrine therapy
  Radiation         Procedure: hormone therapy
  Therapy           Procedure: quality-of-life assessment
                    Procedure: radioprotection
                    Procedure: steroid therapy
                    Procedure: supportive care/therapy

Study ID Numbers: CDR0000530309; NCCTG-N06C4

ClinicalTrials.gov Identifier: NCT00438659

COPYRIGHT 2007 Journal of Drugs in Dermatology, Inc.
COPYRIGHT 2007 Gale Group